170 related articles for article (PubMed ID: 20679509)
41. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
Firsov AA; Smirnova MV; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
[TBL] [Abstract][Full Text] [Related]
42. Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.
Hall Snyder AD; Werth BJ; Nonejuie P; McRoberts JP; Pogliano J; Sakoulas G; Yim J; Singh N; Rybak MJ
Antimicrob Agents Chemother; 2016 Oct; 60(10):5716-23. PubMed ID: 27431211
[TBL] [Abstract][Full Text] [Related]
43. Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis.
LaPlante KL; Woodmansee S
Antimicrob Agents Chemother; 2009 Sep; 53(9):3880-6. PubMed ID: 19564363
[TBL] [Abstract][Full Text] [Related]
44. Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies.
Stratton CW; Liu C; Weeks LS
Antimicrob Agents Chemother; 1987 Aug; 31(8):1210-5. PubMed ID: 2820300
[TBL] [Abstract][Full Text] [Related]
45. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
Lee DK; Kim Y; Park KS; Yang JW; Kim K; Ha NJ
J Biochem Mol Biol; 2007 Nov; 40(6):881-7. PubMed ID: 18047782
[TBL] [Abstract][Full Text] [Related]
46. Activity of daptomycin on biofilms produced on a plastic support by Staphylococcus spp.
Roveta S; Marchese A; Schito GC
Int J Antimicrob Agents; 2008 Apr; 31(4):321-8. PubMed ID: 18201873
[TBL] [Abstract][Full Text] [Related]
47. Unexpected synergistic and antagonistic antibiotic activity against Staphylococcus biofilms.
Dall GF; Tsang SJ; Gwynne PJ; MacKenzie SP; Simpson AHRW; Breusch SJ; Gallagher MP
J Antimicrob Chemother; 2018 Jul; 73(7):1830-1840. PubMed ID: 29554250
[TBL] [Abstract][Full Text] [Related]
48. Effects of subinhibitory concentrations of vancomycin or cefamandole on biofilm production by coagulase-negative staphylococci.
Dunne WM
Antimicrob Agents Chemother; 1990 Mar; 34(3):390-3. PubMed ID: 2334150
[TBL] [Abstract][Full Text] [Related]
49. Rifampicin enhances activity of daptomycin and vancomycin against both a polysaccharide intercellular adhesin (PIA)-dependent and -independent Staphylococcus epidermidis biofilm.
Olson ME; Slater SR; Rupp ME; Fey PD
J Antimicrob Chemother; 2010 Oct; 65(10):2164-71. PubMed ID: 20719763
[TBL] [Abstract][Full Text] [Related]
50. Reversible daptomycin tolerance of adherent staphylococci in an implant infection model.
John AK; Schmaler M; Khanna N; Landmann R
Antimicrob Agents Chemother; 2011 Jul; 55(7):3510-6. PubMed ID: 21576433
[TBL] [Abstract][Full Text] [Related]
51. Activity of cephalosporins against coagulase-negative staphylococci.
Chin NX; Neu NM; Neu HC
Diagn Microbiol Infect Dis; 1990; 13(1):67-9. PubMed ID: 2331853
[TBL] [Abstract][Full Text] [Related]
52. Tigecycline inhibition of a mature biofilm in clinical isolates of Staphylococcus aureus : comparison with other drugs.
Cafiso V; Bertuccio T; Spina D; Purrello S; Stefani S
FEMS Immunol Med Microbiol; 2010 Aug; 59(3):466-9. PubMed ID: 20528931
[TBL] [Abstract][Full Text] [Related]
53. In vitro activity of tigecycline against Staphylococcus epidermidis growing in an adherent-cell biofilm model.
Labthavikul P; Petersen PJ; Bradford PA
Antimicrob Agents Chemother; 2003 Dec; 47(12):3967-9. PubMed ID: 14638511
[TBL] [Abstract][Full Text] [Related]
54.
Zheng JX; Tu HP; Sun X; Xu GJ; Chen JW; Deng QW; Yu ZJ; Qu D
J Med Microbiol; 2020 Jan; 69(1):120-131. PubMed ID: 31916929
[No Abstract] [Full Text] [Related]
55. Vancomycin-resistant Enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin.
Rathe M; Kristensen L; Ellermann-Eriksen S; Thomsen MK; Schumacher H
APMIS; 2010 Jan; 118(1):66-73. PubMed ID: 20041873
[TBL] [Abstract][Full Text] [Related]
56. In vitro activity of tigecycline in combination with gentamicin against biofilm-forming Staphylococcus aureus.
McConeghy KW; LaPlante KL
Diagn Microbiol Infect Dis; 2010 Sep; 68(1):1-6. PubMed ID: 20727462
[TBL] [Abstract][Full Text] [Related]
57. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model.
LaPlante KL; Mermel LA
Nephrol Dial Transplant; 2007 Aug; 22(8):2239-46. PubMed ID: 17403700
[TBL] [Abstract][Full Text] [Related]
58. Effect of daptomycin and vancomycin on Staphylococcus epidermidis biofilms: An in vitro assessment using fluorescence in situ hybridization.
Sutrave S; Kikhney J; Schmidt J; Petrich A; Wiessner A; Kursawe L; Gebhardt M; Kertzscher U; Gabel G; Goubergrits L; Affeld K; Moter A
PLoS One; 2019; 14(8):e0221786. PubMed ID: 31454398
[TBL] [Abstract][Full Text] [Related]
59. In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.
Capone A; Cafiso V; Campanile F; Parisi G; Mariani B; Petrosillo N; Stefani S
Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):625-31. PubMed ID: 26815434
[TBL] [Abstract][Full Text] [Related]
60. Comparative time-kill study of doxycycline, tigecycline, cefazolin and vancomycin against several clones of Staphylococcus aureus.
Herrera M; Mobilia L; Posse G; Limansky A; Ballerini V; Bantar C
Curr Clin Pharmacol; 2013 Nov; 8(4):332-9. PubMed ID: 23590512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
